Mira Pharmaceuticals to Acquire BioGenetics
Ticker: MIRA · Form: 8-K · Filed: Nov 19, 2024 · CIK: 1904286
| Field | Detail |
|---|---|
| Company | Mira Pharmaceuticals, Inc. (MIRA) |
| Form Type | 8-K |
| Filed Date | Nov 19, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, pipeline-expansion
TL;DR
Mira Pharma buying BioGenetics, Q1 2025 close, pipeline boost incoming.
AI Summary
Mira Pharmaceuticals, Inc. announced on November 19, 2024, that it has entered into a definitive agreement to acquire all outstanding equity interests of BioGenetics, Inc. The transaction is expected to close in the first quarter of 2025, subject to customary closing conditions. This acquisition is anticipated to significantly expand Mira Pharmaceuticals' product pipeline and market reach.
Why It Matters
This acquisition could significantly bolster Mira Pharmaceuticals' market position and product offerings in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges and potential overvaluation, which could impact Mira Pharmaceuticals' financial performance.
Key Players & Entities
- Mira Pharmaceuticals, Inc. (company) — Registrant
- BioGenetics, Inc. (company) — Target company for acquisition
- November 19, 2024 (date) — Date of report and announcement
- First quarter of 2025 (date) — Expected closing period for the acquisition
FAQ
What is the primary purpose of this Form 8-K filing?
This Form 8-K is filed to report on other events, specifically Mira Pharmaceuticals, Inc.'s entry into a definitive agreement to acquire BioGenetics, Inc.
When is the acquisition of BioGenetics, Inc. expected to be completed?
The acquisition is expected to close in the first quarter of 2025, subject to customary closing conditions.
What is the former name of Mira Pharmaceuticals, Inc.?
The former name of Mira Pharmaceuticals, Inc. was Mira1a Therapeutics, Inc., with a date of name change on January 12, 2022.
Where is Mira Pharmaceuticals, Inc. headquartered?
Mira Pharmaceuticals, Inc.'s principal executive offices are located at 1200 Brickell Avenue, Suite 1950 #1183, Miami, Florida 33131.
What is the SIC code for Mira Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code for Mira Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 844 words · 3 min read · ~3 pages · Grade level 14.9 · Accepted 2024-11-19 16:10:02
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share MIRA The Nasdaq
Filing Documents
- form8-k.htm (8-K) — 37KB
- 0001493152-24-046812.txt ( ) — 212KB
- mira-20241119.xsd (EX-101.SCH) — 3KB
- mira-20241119_lab.xml (EX-101.LAB) — 33KB
- mira-20241119_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MIRA PHARMACUTICALS, INC. Dated: November 19, 2024 By: /s/ Erez Aminov Name: Erez Aminov Title: Chief Executive Officer